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PURPOSE. In contrast to neovascular AMD (nAMD), no treatment option exists for dry AMD.
Hence, the identification of specific biomarkers is required to facilitate diagnosis and therapy
of dry AMD.
METHODS. The proteome of 34 vitreous humor samples (dry AMD: n ¼ 6; nAMD: n ¼ 10;
proliferative diabetic retinopathy [PDR]: n ¼ 9; epiretinal membrane [ERM]: n ¼ 9) was
analyzed by liquid chromatography coupled mass spectrometry. Then, label-free relative
quantification of dry AMD, nAMD, and PDR relative to ERM, which was defined as the
reference group, was performed. Application of a bioinformatics pipeline further analyzed the
vitreous proteome by cluster and gene set enrichment analysis. A selection of differentially
regulated proteins was validated by ELISA.
RESULTS. A total of 677 proteins were identified in the vitreous of the four patient groups and
quantified relatively to ERM. Different clusters of regulated proteins for each patient group
were identified and showed characteristic enrichment of specific pathways including
‘‘oxidative stress’’ for dry AMD, ‘‘focal adhesion’’ for nAMD, and ‘‘complement and
coagulation cascade’’ for PDR patients. We identified cholinesterase (CHLE) to be specifically
upregulated in dry AMD and ribonuclease (pancreatic; RNAS1) together with serine
carboxypeptidase (probable; CPVL) to be upregulated in both forms of AMD.
CONCLUSIONS. The described pathways specific for the different patient groups and the
identification of characteristic differentially regulated proteins provide a first step toward the
definition of biomarkers for dry AMD. The presented data will facilitate the investigation of
mechanistic connections of proteins to the respective disease.
Keywords: proteomics, biomarker, vitreous humor, dry AMD, nAMD
AMD is a major cause of irreversible and progressive visionloss among the elderly in the Western world.1–3 Two
patterns of retinal changes are typically distinguished and
categorized as dry AMD or neovascular AMD (nAMD).4 Dry
AMD, which affects 85% to 90% of AMD patients5,6 is
characterized by the loss of RPE and subsequent atrophy of
the neuroretinal tissue. nAMD is defined by the growth of new
blood vessels from the choroid toward or into the retina,
resulting in hemorrhages, leakage, and swelling of the neuro-
retinal tissue, eventually leading to subretinal scar formation.4
Whereas in dry AMD, deterioration of vision occurs slowly,
vision loss in nAMD often happens within a few months.7–9
Risk factors for the development of AMD include age,
cigarette smoking, high body mass index, and genetic variants,
mainly within the complement system.10–15 In addition, age-
dependent reduction of choroidal perfusion and resulting
chronic tissue hypoxia in the retina may contribute to disease
progression.16 Research into the pathogenesis of nAMD has led
to the development of drugs that target the hypoxia-induced
VEGF and its signaling pathway. These drugs prevent or slow
down loss of vision in the vast majority of patients with
nAMD.17–20
For dry AMD, however, no treatment option exists. Thus,
research focuses on the molecular basis of dry AMD to identify
biomarkers for diagnosis and as therapeutic targets. Because
direct sampling of human retina for research is difficult,
alternative tissues are required as substitutes. Vitreous humor
(VH) is considered a good surrogate to identify disease-specific
alterations due to its close proximity to the retina, based on its
at least partial reflection of the physiologic and pathologic
state21,22 and its accessibility during vitreoretinal surgery.23–25
Recently, mass spectrometry (MS)-based proteomics has
provided a means for global proteome characterization of the
human VH26–28 and also for the analysis of ocular fluids in
different eye conditions including cataract,29 idiopathic epi-
retinal membranes,30 hematogenous retinal detachment with
proliferative vitreoretinopathy,31 nAMD,32,33 and diabetic reti-
nopathy (DR).23–25
Here, we analyzed the VH proteome of eyes from patients
affected by either dry AMD, nAMD, proliferative diabetic
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retinopathy (PDR), or idiopathic epiretinal membranes (ERM)
by liquid chromatography coupled MS (LC-MS/MS) and
performed label-free relative quantification. Our results pro-
vide (1) the first report of the human VH proteome of patients
affected by dry AMD; (2) a direct comparison of the dry AMD,
nAMD, and PDR VH proteomes; and (3) an extended view on
the major regulated pathways and characteristically regulated
proteins for the different patient groups.
METHODS
VH Patient Sample Collection
The study was approved by the ethics committee of Zurich,
Switzerland, and adhered to the tenets of the Declaration of
Helsinki. All study subjects were recruited among patients who
were scheduled for elective cataract surgery or vitrectomy.
Signed informed consent was obtained from each subject prior
to participation. Exclusion criteria were as follows: glaucoma,
intraocular surgery within the last 6 months, ocular medica-
tions other than lubricants, intraocular inflammation, non-
proliferative diabetic retinopathy, myopia of more than 6
diopters spherical equivalent, any other ocular vascular
disease, previous retinal detachment, previous vitrectomy,
retinal degenerative disease, and presence of any other retinal
condition potentially affecting either function or oxygenation
of the retina other than nAMD, dry AMD, or PDR.
Of 38 patients enrolled to this single-centered study at the
Department of Ophthalmology of the University Hospital
Zurich, 34 (dry AMD, n ¼ 6; nAMD, n ¼ 10; PDR, n ¼ 9;
ERM, n ¼ 9) were included in data analysis. Epidemiologic
details of included patients are summarized in Supplementary
Table S1. Four samples were excluded from further analysis for
technical reasons (Supplementary Figs. S1A, S1B).
VH biopsies were collected during planned surgery, either
by standard pars plana vitrectomy or the needle-tap tech-
nique34 using a 25-gauge needle inserted 3.5 mm behind the
limbus in the temporal inferior quadrant of the globe. VH
samples were aspirated form the vitreous core at the start of
the surgery, right after disinfection and draping. In case of
cataract surgery, VH was aspirated as a first step before starting
any procedure at the lens or cornea. In cases of pars plana
vitrectomy, the vitreous was taken after inserting the first port
in the temporal inferior quadrant before the infusion line was
inserted. On average, approximately 500 lL VH were taken,
independent of the used procedure. Samples were aliquoted,
snap frozen, and stored in liquid nitrogen.
Sample Preparation and MS Measurement
VH samples were subjected to Agilent’s Plasma 7 Multiple
Affinity Removal Spin Cartridge system (MARS Hu-7; Agilent
Technologies, Basel, Switzerland) for the depletion of the
seven high abundant proteins (albumin, IgG, antitrypsin, IgA,
transferrin, haptoglobin, and fibrinogen) according to the
adapted depletion protocol by Murthy et al.26 Depleted flow
through was then pooled, desalted, and concentrated by 3-kDa
nominal molecular weight limit (NMWL) low-adsorption filter
membranes (Amicon Ultra-4; Merck Millipore, Schaffhausen,
Switzerland). Five micrograms protein of depleted samples was
subjected to filter-assisted sample preparation (FASP)-digest
adapted from Wis´niewski et al.,35 with a subsequent desalting
step by C18 solid phase extraction columns (Sep-Pak Fenis-
terre; Waters Corp., Milford, MA, USA). Desalted tryptic
peptides were lyophilized and resolubilized in 0.1% formic
acid (FA). Shotgun proteomics analysis was performed on a
high-resolution Fourier transformation mass spectrometer
(Orbitrap Fusion; Thermo Fisher Scientific, Bremen, Germany)
coupled to a nano-HPLC system (EASY-nLC 1000; Thermo
Fisher Scientific). High accuracy mass spectra were acquired in
the mass range of 300 to 1500 m/z and a target value of 43105
ions in Orbitrap MS1, followed by top-speed MS2 via
quadrupole isolation, higher energy collisional dissociation
(HCD) fragmentation, and detection in the ion trap. Target ions
already selected for MS2 were dynamically excluded for 25
seconds.
Protein Identification and Quantification
ProgenesisQI for proteomics software (version 3.0.5995;
Nonlinear Dynamics Ltd., Tyne, UK) was used for MS1
intensity-based label-free relative quantification. The feature
maps of all samples were aligned to the measurement of a
representative pool of four samples per patient group. Peptides
with a charge state of 2þ to 5þ were used for quantification.
Top five tandem mass spectra were exported using charge
deconvolution and deisotoping option at a maximum number
of 200 peaks per MS2. The export was searched with Mascot
database (version 2.5.1; Matrix Science, London, UK) using the
following search parameters: maximum missed cleavages: 2;
peptide mass tolerance: 10 ppm (# 13C¼ 1); and fragment ion
tolerance: 0.5 Da. Carbamidomethyl on cysteine was specified
as fixed, whereas oxidation on methionine and acetylation at
the protein N terminus were specified as variable modifica-
tions. Searches against the human protein database (Taxonomy
ID: 9606) from UniProt (59,783 entries; downloaded at
02.09.2016) concatenated to a decoy (reversed) database and
260 known MS contaminants were performed. A target-decoy
approach was used to estimate the false-discovery levels.36
Proteins with single peptide assignment and decoy hits were
excluded from further analysis. For protein quantification, the
normalized abundance of all nonconflicting peptide ions of the
same protein group were summed together individually for
each sample to generate the normalized quantitative protein
abundance. Dry AMD, nAMD, and PDR patient groups were
relatively quantified to the ERM patient group by pairwise
comparison. Fold changes (FCs) were calculated, and statistical
significance was determined by 1-way ANOVA on the
hyperbolic arcsine transformed normalized protein abundance.
A protein was defined to be significantly differentially regulated
if it reached a jlog2(FC)j > 0.58 with P < 0.05.
ELISA Measurement
Complement factor I (CFAI; Abnova, Walnut, CA, USA),
chitinase-3-like protein 1 (CH3L1; Abnova), d-aminolevulinic
acid dehydratase (HEM2; Cloud Clone Corp., Katy, TX, USA),
ribonuclease pancreatic (RNAS1; Cloud Clone Corp.), super-
oxide dismutase (SODC; Abnova), VEGFA (Cloud Clone Corp.),
and VEGF receptor 1 (VGFR1; Cloud Clone Corp.) have been
selected to be measured by sandwich-ELISA in human VH
samples based on the proteomics data or their known
involvement in neovascularization (VEGFA). Assays were
performed according to manufacturer’s instructions.
Bioinformatics
Gene ontology (GO) term enrichment and protein–protein
interaction network analysis of significantly differentially
regulated proteins was performed by the STRING database
(version 10.5).37 Proteins were categorized in the respective
parental GO-terms ‘‘biological process’’ (GO-BP), ‘‘molecular
function’’ (GO-MF), and ‘‘cellular component’’ (GO-CC)
separately. The minimal interaction score was set to 0.3.
Identification of proteases in the vitreous proteome was
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performed by comparison of all significantly differentially
regulated proteins to a database of all known human proteases
(version 12; MEROPS DB).38
Volcano plots were generated by R (version 3.4.1)39 with
the RcolorBrewer (version 1.1-2 by Erich Neuwirth) package.
Hierarchical Pearson clustering of log2-transformed normalized
relative abundances, centered by subtraction of the average
relative abundance of each protein was visualized by heatmap
using the R package pheatmap (version 1.0.8 by Raivo Kolde).
The area-proportional Venn diagram was generated by
BioVenn.40 Webgestalt (version 2017)41 together with data
mapping to wikipathways.org42 was used for gene set
enrichment analysis (GSEA) from gene lists ranked by log2(FC)
as described by Subramanian et al.43 The significance threshold
for the enrichment was set to a false discovery rate (FDR) of
0.25.
Statistical analysis of epidemiologic and ELISA data was
performed by Prism 6 software (version 6.0f; GraphPad
Software, La Jolla, CA, USA). All data are presented as means
6 SD. One-way ANOVA with Holm-Sˇ´ıda´k correction for
multiple comparisons was used to determine statistical
significance relative to ERM group. P < 0.05 was considered
significant.
RESULTS
Proteomic Analysis
Of the 38 patient samples measured by LC-MS/MS, 4 samples (2
PDR and 2 ERM) were excluded for technical reasons
(Supplementary Figs. S1A, S1B). The remaining 34 samples
(dry AMD: n¼ 6; nAMD: n¼ 10; PDR: n¼ 9; ERM: n¼ 9) were
analyzed in detail. Immunodepletion by MARS Hu-7 columns
reduced the high abundant blood proteins in VH samples 10- to
500-fold (Supplementary Fig. S2).
LC-MS/MS measurements identified a total of 1,162 different
proteins in the four patient groups, of which 677 were
quantifiable (Supplementary Table S2) with an estimated FDR
close to 0. The MS proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE44 partner repos-
itory with the dataset identifier PXD008354.
Comparison of Patient Groups
Heatmap representation of normalized relative abundances
with hierarchical clustering for proteins allowed the compar-
ison of the different patient groups, as well as the identification
of similarly regulated protein clusters (Fig. 1A). Two main
clusters of upregulated proteins (shades of red) discriminated
PDR (lower branch of dendrogram) from nAMD (upper branch
of dendrogram) patient samples. Interestingly some patients of
the dry AMD group showed similar protein regulation as
patients of the nAMD group, even though they were not
diagnosed with nAMD. Similarly, some nAMD samples showed
a pattern comparable to the PDR group. In general, the
strongest upregulation was observed for proteins in the PDR
patient group.
To gain an initial overview, GO term enrichment (Fig. 1B)
and protein–protein interaction network analysis (Fig. 1C;
Supplementary Fig. S3) of significantly differentially regulated
proteins of the patient groups was performed by STRING
database. Comparison of enriched GO-BP terms identified
response to stress for both dry AMD (FDR: 1.2 3 103) and
nAMD (FDR: 3.33 3 106) and regulation of endopeptidase
(FDR: 4.233 1015) for PDR as strongest enriched terms. GO-
MF enriched strongly for processes related to protein binding,
such as cell adhesion molecule binding for dry AMD (FDR: 1.7
3 103), glycoprotein binding for nAMD (FDR: 9.03 103), and
glycosaminoglycan binding for PDR (FDR: 2.5 3 1018).
Interestingly, extracellular region, extracellular exosome, and
membrane bounded vesicle were the strongest enriched three
terms for GO-CC in both forms of AMD (FDR: < 3.73 1012).
Of those, only membrane-bounded vesicle was identified
among the top three in PDR (FDR: 3.4 3 1040). Protein–
protein interaction network analysis for dry AMD identified
VEGF receptor 2 (KDR), fibronectin (FN1), and intercellular
adhesion molecule 1 (ICAM1) to be the network nodes with
the highest degree of interaction (i.e., number of connections
to other nodes) (Fig. 1C). For nAMD, this analysis identified
cathepsin B (CTSB), superoxide dismutase 1 (SODC), and
retinal dehydrogenase 1 (ALDH1A1) as the central nodes (Fig.
1C), whereas amyloid-b A4 protein (APP), kininogen-1 (KNG1),
and metalloproteinase inhibitor 1 (TIMP1) were found to be
the nodes with the highest degree for PDR (Supplementary Fig.
S3). Of the 677 quantifiable proteins, 11 were associated with
cytokine activity (GO:0005125), 12 to growth factor activity
(GO:0008083), and 34 to response to hypoxia (GO:0001666).
Mapping of all identified proteins to the MEROPS protease
database identified 74 different proteases in our dataset
(Supplementary Tables S3 and S4).
Top Regulated Proteins
Our analysis identified 34 proteins (4 up- and 30 downregu-
lated) for dry AMD, 33 proteins (30 up- and 3 downregulated)
for nAMD, and 142 proteins (84 up- and 58 downregulated) for
PDR to be significantly regulated relative to ERM (Fig. 2A).
Comparison of these proteins revealed that most were unique
to a specific patient group (Fig. 2B). Only ribonuclease
(pancreatic; RNAS1) and serine carboxypeptidase (probable;
CPVL) were common for dry- and nAMD, as were b-2-
microglobulin (B2MG), 14-3-3 protein c (1433G), retinal
dehydrogenase 1 (AL1A1), and protein DJ-1 (PARK7) for nAMD
and PDR. Because nAMD and PDR have a common neovascular
component, it will be of interest to test whether these proteins
are relevant for neovascular processes. The largest overlap was
observed for dry AMD and PDR. Proteins detected in the
vitreous of both patient groups included HEM2, lithostathine-1-
a (REG1A), ICAM1, ribonuclease 4 (RNAS4), scavenger
receptor cysteine-rich type 1 protein M130 (F5GZZ9), car-
boxypeptidase (X6R5C5), actin (cytoplasmic 2; ACTG), and
neurosecretory protein VGF (VGF). No protein was found that
was differentially regulated in all patient groups.
It is striking that the vast majority (88%) of differentially
regulated proteins in dry AMD were downregulated. HEM2,
RNAS1, CPVL and cholinesterase (CHLE) were the only four
proteins found to be upregulated (Table 1). In contrast, more
proteins were up- than downregulated in both nAMD (91%)
and PDR (59%). VGFR1, important for the regulation of
neovascularization, was the strongest upregulated factor in
nAMD, followed by 1433G and AL1A1 (Table 1). The top
three upregulated proteins found in PDR were hemoglobin
subunit b (HBB), carbonic anhydrase 1 (CAH1), and HEM2
(Table 1).
GSEA and Pathway Mapping
Although identification of specific differentially regulated
proteins in individual patient groups is critical for disease
characterization and the definition of potential biomarkers, it is
of equal importance to describe affected protein and gene
networks to approach pathologic mechanisms, even if single
members of such networks may not reach significance by the
stringent filter criteria set for protein regulation. Thus,
potentially relevant gene networks were identified by GSEA,
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FIGURE 1. Comparison of the patient groups by heatmap and GO-term analysis. (A) Heatmap of normalized relative quantification values with
hierarchical Pearson clustering for proteins. Log2 of quantitative values, centered by subtraction of average values for each protein, is displayed.
Higher abundance of a specific protein than average is displayed in shades of red, whereas reduced abundance is displayed in shades of blue. (B)
STRING GO-term enrichment of all significantly differentially regulated proteins (jlog2(FC)j > 0.58; P < 0.05) in each patient group. The three
strongest enriched GO-terms for each of the three parental GO-term categories GO-MF, GO-BP, and GO-CC are listed. (C) STRING protein–protein
interaction networks of dry AMD and nAMD patient group, based on significantly differentially regulated proteins (jlog2(FC)j > 0.58; P < 0.05).
Color gradient corresponds to log2(FC), node size to clustering coefficient, and edge width to STRING association score.
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and enriched proteins were mapped to pathway maps (Table
2). Although for dry AMD, no pathway reached the significance
threshold, oxidative stress was closest (FDR: 0.261; Table 2)
and included glutathione peroxidase 3 (GPX3), superoxide
dismutase 1 and 3 (SOD1, SOD3), and catalase (CAT) that all
showed a trend for upregulation (Supplementary Table S2). For
nAMD, the pathway focal adhesion that included FLT1 and
KDR, the genes encoding VGFR1 and VGFR2, respectively, had
the lowest FDR (0.004) (Table 2). For PDR patients, the
pathway complement and coagulation cascade (FDR: 0.024)
was among the most enriched pathways (Table 2).
Validation of Proteomics Data by ELISA
Seven proteins identified by proteomics were validated (Fig. 3),
and their concentrations determined (Supplementary Table S5)
by ELISA. The ELISA data matched the proteomics-based
expression pattern of CFAI, CH3L1, HEM2, and SODC in the
different patient groups. However, the upregulation of RNAS1
in dry AMD and nAMD and of VGFR1 in nAMD was not
reproduced.
Levels of VEGFA, the main regulator of neovascularization,
were also determined by ELISA, despite its absence in our
proteomics data set. It showed a slight trend toward elevated
levels in PDR patients, whereas the other patient groups,
including nAMD, did not show any regulation (Fig. 3).
DISCUSSION
AMD is a major cause of blindness or visual impairment in
developed countries and the third major cause globally.45,46
Whereas anti-VEGF therapies can prevent disease progression
in nAMD and PDR, no treatment options exist for the highly
prevalent dry form of AMD. The identification of biomarkers
would not only facilitate diagnosing patients early during
disease but also help to understand disease mechanisms and to
develop therapies. To use biomarkers in clinics, both the
FIGURE 2. Volcano plots and Venn diagram. (A) Volcano plots of all quantified proteins in the respective patient groups relative to the ERM patient
group. Significantly differentially regulated proteins (jlog2(FC)j > 0.58; P < 0.05) are displayed in red. (B) Venn diagram identifying the number of
significantly differentially regulated proteins, which were common to more than one patient group.
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nature of the tissue for analysis and the ease of material
sampling must be considered. The VH might be ideal due to its
proximity to the retina and its accessibility during vitreoretinal
surgery. Thus, several studies used the human VH for MS-based
proteomics, but all focused on PDR21,23,25,47,48 and nAMD.32,33
Studies concentrating on dry AMD mainly analyzed the
composition of drusen,49,50 the choroid/Bruch membrane
complex,51 or the RPE52 of post mortem eyes. Here, we
TABLE 1. Significantly Upregulated Proteins for Each Patient Group
Protein Name Gene Name Description FC P Value
Dry AMD
HEM2 ALAD d-aminolevulinic acid dehydratase 5.5 0.035
RNAS1 RNASE1 Ribonuclease pancreatic 2.4 0.009
CPVL CPVL Probable serine carboxypeptidase CPVL 2.1 0.047
CHLE BCHE Cholinesterase 1.7 0.029
nAMD
VGFR1 FLT1 Vascular endothelial growth factor receptor 1 8.2 0.047
1433G YWHAG 14-3-3 protein c 6.0 0.002
AL1A1 ALDH1A1 Retinal dehydrogenase 1 4.6 0.040
FRIH FTH1 Ferritin heavy chain 4.3 0.021
GILT IFI30 c-interferon–inducible lysosomal thiol reductase 3.2 0.040
CH3L1 CHI3L1 Chitinase-3-like protein 1 3.2 0.007
GSHR GSR Isoform 2 of glutathione reductase, mitochondrial 3.1 0.041
PARK7 PARK7 Protein DJ-1 2.5 0.018
MASP2 MASP2 Mannan-binding lectin serine protease 2 2.4 0.023
PGAM2 PGAM2 Phosphoglycerate mutase 2 2.3 0.010
PDR
HBB HBB Hemoglobin subunit b 107.8 0.049
CAH1 CA1 Carbonic anhydrase 1 47.7 0.033
HEM2 ALAD d-aminolevulinic acid dehydratase 34.7 0.040
SAA1 SAA1 Serum amyloid A-1 protein 26.9 0.009
RINI RNH1 Ribonuclease inhibitor 24.7 0.026
CATA CAT Catalase 18.0 0.007
CAH2 CA2 Carbonic anhydrase 2 17.8 0.044
FIBB FGB Fibrinogen b chain 16.4 0.004
GUC2A GUCA2A Guanylin 16.1 0.001
FIBG FGG Isoform c-A of fibrinogen c chain 14.5 0.002
TABLE 2. Top Five GSEA Positively Enriched Pathways for Each Patient Group
Wiki PW ID Enriched Pathway FDR NES* Enriched Genes
Dry AMD
WP408 Oxidative stress 0.261 1.71 GPX3; SOD1; SOD3; CAT
WP1533 Vitamin B12 metabolism 0.441 1.34 ALB; HBA1; HBB; SOD1
WP176 Folate metabolism 0.485 1.48 ALB; GPX3; HBA1; HBB; SOD1; CAT
WP15 Selenium micronutrient network 0.542 1.16 ALB; GPX3; HBA1; HBB; SOD1; CAT
WP2064 Neural crest differentiation 0.554 1.36 CDH6
nAMD
WP306 Focal adhesion 0.004 1.85 COL11A1; FLNA; FLT1; KDR; ACTB; TLN1; ACTG1
WP51 Regulation of actin cytoskeleton 0.007 1.80 CFL1; MSN; PFN1; ACTB; ACTG1; EZR
WP289 Myometrial relaxation and contraction
pathways
0.012 1.75 GUCA2A; ACTB; ACTC1; ACTG1; YWHAV; YWHAG;
YWHAZ; CALM1; GSTO1
WP2884 NRF2 pathway 0.049 1.65 FTH1; FLT; GSR; GSTP1; HSP90AA1; PGD;
SERPINA1; CBR1
WP534 Glycolysis and gluconeogenesis 0.081 1.58 ENO1; FBP1; ALDOA; ALDOC; GAPDH; GPI;
LDHA; MDH1; PGAM2; PGK1; PKM; TPI1
PDR
WP15 Selenium micronutrient network 0.016 1.83 CRP; GSR; HBA1; HBB; APOB; SAA1; PRDX2; CAT
WP558 Complement coagulation cascades 0.024 1.78 MASP2; CPB2; CFD; F2; F9; F12; F13B; FGB;
SERPIND1; CFI; KLKB1; KNG1; SERPINC1;
SERPINA5; PLG; SERPINF2; PROS1; CFB;
SERPING1; C1QB; C1R; C1S; C2; C3; C4B; C6;
C7; C8G; C9; VWF
WP2884 NRF2 pathway 0.056 1.66 FTH1; FTL; GSR; PGD; BLVRB; PRDX6
WP176 Folate metabolism 0.060 1.69 CRP; HBA1; HBB; APOB; SAA1; CAT
WP1533 Vitamin B12 metabolism 0.070 1.66 CRP; HBA1; HBB; APOB; SAA1
* Normalized enrichment score.
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directly compared the VH proteome of dry AMD, nAMD, PDR,
and ERM patients.
We found that 195 of the 677 proteins identified in our
patient groups were significantly regulated (Fig. 2B). Of the 34
proteins identified in dry AMD, only HEM2, RNAS1, CPVL, and
CHLE were upregulated. The only protein upregulated solely in
dry AMD was CHLE. It is a ubiquitously expressed protein that
regulates cell proliferation in embryonic tissues and the onset
of differentiation during early neuronal development.53 CHLE
has neuroprotective potential and is used to prevent nerve
agent toxicity54 and, in a modified form, as cocaine addiction
therapeutic.55 HEM2 was upregulated also in PDR and is
involved in catalyzing the condensation of d-aminolevulinic
acid (ALA) to porphobilinogen.56 This activity may reduce
oxidative stress as ALA is a potential source of reactive oxygen
species due to autoxidation.57 CPVL, an enzyme potentially
involved in antigen processing,58 was upregulated in dry AMD
and nAMD but downregulated in PDR. Interestingly, a single
nucleotide polymorphism (SNP) in a haplotype block that
included CPVL was associated with diabetic retinopathy in
Chinese patients.59 Similar to CPVL, RNAS1, which is secreted
and responsible for the degradation of extracellular RNA,60–62
was upregulated in dry AMD and nAMD.
Choroidal or retinal neovascularization are central hallmarks
of nAMD and PDR, respectively.63 The most prominent and
therapeutically relevant factor for neovascularization is VEGF,
overexpressed either from the RPE (nAMD) or pericytes
(PDR).64,65 However, our own and most of the published VH
discovery proteomics studies performed by MS did not detect
VEGF as differentially regulated factor.23–25,33,47 The generally
low levels of VEGF and only minor concentration changes in
focal areas may explain the lack of detection by global methods
such as LC-MS/MS.47 ELISA, however, detected VEGF and
showed increased (nonsignificant) levels in PDR but not nAMD
(Fig. 3). In contrast, VGFR1 (8.23, P ¼ 0.047; Table 1) and
VGFR2 (1093, nonsignificant), the two receptors for VEGF,
were upregulated in nAMD, but only VGFR2 (2.63, nonsignif-
icant) was found increased also in PDR (Supplementary Table
S2). The varying regulation of these factors might be explained
by the treatment of nAMD and PDR patients with anti-VEGF or
laser photocoagulation therapy, respectively.
As oxidative stress due to cigarette smoke,66 exposure to
sunlight,67 and other environmental factors is likely contribut-
ing to AMD development, it may be of significance that the
NRF2 pathway that regulates a protective antioxidant re-
sponse68 was found enriched in nAMD and PDR by GSEA
analysis (Table 2). Oxidative stress may also be important for
dry AMD69 because GPX3, SOD1, SOD3, and CAT involved in
the regulation of reactive oxygen species and part of the
oxidative stress pathway were upregulated (Table 2; Supple-
mentary Table S2), even though enrichment was weak (FDR:
0.261).
For nAMD, the focal adhesion pathway was strongly
enriched (0.004 FDR; Table 2). This may correlate to the
reported high incidence of focal vitreomacular adhesions at the
site of choroidal neovascularization in nAMD patients.70
Further, the enrichment of the pathway for glycolysis and
gluconeogenesis (FDR: 0.081) potentially indicates a metabolic
shift to aerobic glycolysis. Increased levels of lactate dehydro-
genase (LDHA; Table 2; Supplementary Table S2) could be a
consequence of the Warburg effect as it has been reported for
nAMD patients.71 Increased conversion of pyruvate to lactate
as it occurs during glycolysis is also suggested by data showing
higher urinary lactate/pyruvate ratios in nAMD patients.72
Low level complement activation is part of the immune
tolerance in the immune privileged eye.73 Dysregulation of the
complement system has been linked to AMD,74 and genome-
wide association studies have identified several SNPs in genes
of the complement system to be risk factors for the
development of AMD75 and PDR.76 Similarly to our data
showing a strong enrichment (FDR: 0.024) of the pathway
complement and coagulation cascade in PDR patients with
significant upregulation of 11 of 27 mapped proteins, an
enrichment of complement cascade components in the VH of
FIGURE 3. Validation of proteomics data by ELISA. Comparison of protein abundance measured by ELISA (blue) to LC-MS/MS based proteomics
(red) measurements. Protein levels were expressed relative to the ERM patient group. Shown are means 6 SD. *P < 0.05; **P < 0.01.
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PDR patients has been reported.47 Conversely in dry AMD
patients, complement factor H (CFAH) and complement factor
H-related protein 1 (FHR1)—the only components of the
alternative pathway able to suppress complement activation
on extracellular matrix75—showed reduced levels (Supple-
mentary Table S2).
As expected for a mostly acellular structure such as the VH,
GO-CC was strongly enriched for extracellular terms including
extracellular region in dry AMD and nAMD and extracellular
space and others in PDR (Fig. 1B). Nevertheless, total GO-CC
categorization revealed that a majority (56%) of all identified
proteins were membrane associated or intracellular. Because 7
(APOE; MYH9; PHLD; Q5H9A7; TIMP2; DAG1; and ERAP1) of
the 74 identified human proteases belonged to a disintegrin
and metalloprotease (ADAM) family, increased ectodomain
shedding may explain this observation, as has been suggested
for PDR patients.47
CONCLUSIONS
The direct comparison of the VH proteome of dry AMD, nAMD,
and PDR to ERM patients identified different clusters of
upregulated proteins for each patient group and showed
characteristic enrichment of specific pathways, such as
oxidative stress for dry AMD, focal adhesion for nAMD, and
complement and coagulation cascade for PDR. We identified
CHLE to be specifically upregulated in dry AMD and RNAS1
together with CPVL to be upregulated in both forms of AMD.
The relevance of these factors needs to be investigated in
additional studies with larger patient cohorts.
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